Figure 2.

Nasal Symptom Scale scores by time and treatment. Results from an 8-hour period of at-home ratings by subjects following the laboratory-based Nasal Allergen Challenge. Because not all subjects underwent the full dose-response in the laboratory, the results above represent symptoms following a maximum dose of 250, 1250, or 6250 AU/ml from, respectively, 5, 2, and 13 subjects in the Placebo treatment condition; 6, 1, and 13 subjects in the loratadine treatment condition; and 4, 2, and 13 subjects in the CBP treatment condition.

Corren et al. Nutrition Journal 2008 7:20   doi:10.1186/1475-2891-7-20
Download authors' original image